XML 44 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Business Segment Information
12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Business Segment Information
22. Business Segment Information
The Company
has
three
reportable segments, BSI Life Science, BSI N
a
no
 and BEST, as discussed in Note 1 to the
consolidated
financial statements.
Selected reportable segment information is presented below (in millions):
    
2021
    
2020
    
2019
 
Revenue:
                          
BSI Life Science
   $ 1,510.6      $ 1,253.9      $ 1,244.9  
BSI N
ano
     697.5        556.1        632.7  
BEST
     223.8        189.5        209.9  
Eliminations (a)
     (14.0      (12.0      (14.9
    
 
 
    
 
 
    
 
 
 
Total revenue
   $ 2,417.9      $ 1,987.5      $ 2,072.6  
    
 
 
    
 
 
    
 
 
 
Operating Income:
                          
BSI Life Science
   $ 385.4      $ 273.8      $ 290.3  
BSI N
ano
     73.4        23.6        40.4  
BEST
     22.2        6.2        16.4  
Corporate, eliminations and other (b)
     (67.7
     (55.3
  
  (46.2
    
 
 
    
 
 
    
 
 
 
Total operating income
   $ 413.3      $ 248.3      $ 300.9  
    
 
 
    
 
 
    
 
 
 
 
(a)
Represents product and service revenue between reportable segments.
(b)
Represents corporate costs and eliminations not allocated to the reportable segments.
Total assets by segment are as follows (in millions):
 
    
2021
    
2020
 
Assets:
                 
BSI Life Science, BSI N
ano
 & Corporate
   $ 3,560.5      $ 2,964.5  
BEST
     97.9        88.7  
Eliminations and other (a)
     (8.4      (4.2
    
 
 
    
 
 
 
Total assets
   $ 3,650.0      $ 3,049.0  
    
 
 
    
 
 
 
 
(a)
Assets not allocated to the reportable segments and eliminations of intercompany transactions.
The Company is unable, without unreasonable effort or expense to disclose the amount of total assets by the BSI Life Science and BSI
Nano
Segments as well as the Corporate function and further, the Company’s chief operating decision maker does not receive any asset information by operating segment.

 
Total capital expenditures and depreciation and amortization by segment are presented below (in millions):
 
    
2021
    
2020
    
2019
 
Capital Expenditures:
                          
BSI Life Science
   $ 61.3      $ 59.1      $ 44.4  
BSI N
ano
     16.8        10.6        18.5  
Corporate
     4.7        17.4        4.7  
BEST
     9.2        10.1        5.4  
    
 
 
    
 
 
    
 
 
 
Total capital expenditures
   $ 92.0      $ 97.2      $ 73.0  
    
 
 
    
 
 
    
 
 
 
Depreciation and Amortization:
                          
BSI Life Science
   $ 41.1      $ 35.0      $ 30.5  
BSI
N
ano
     37.4        35.7        35.9  
Corporate
     4.3        4.0        3.8  
BEST
     6.3        5.7        5.4  
    
 
 
    
 
 
    
 
 
 
Total depreciation and amortization
   $ 89.1      $ 80.4      $ 75.6  
    
 
 
    
 
 
    
 
 
 
Revenue and long-lived assets (including property, plant and equipment, net and operating lease right of use assets) by geographical area are as follows (in millions):

 
 
  
2021
 
  
2020
 
  
2019
 
Revenue:
                          
United States
   $ 601.0      $ 455.9      $ 529.8  
Germany
     262.6        244.9        213.6  
Rest of Europe
     658.1        519.8        505.2  
Asia Pacific
     729.1        629.1        651.0  
Other
     167.1        137.8        173.0  
    
 
 
    
 
 
    
 
 
 
Total revenue
   $ 2,417.9      $ 1,987.5      $ 2,072.6  
    
 
 
    
 
 
    
 
 
 
 
 
  
2021
 
  
2020
 
  
2019
 
Long-lived assets:
  
  
  
United States
  
$
51.3     
$
61.3     
$
53.2  
Germany
     244.0     
 
227.8     
 
175.1  
Rest of Europe
     141.5     
 
144.7     
 
118.3  
Asia Pacific
     22.6     
 
22.1     
 
16.4  
Other
     6.6     
 
7.1     
 
8.7  
    
 
 
    
 
 
    
 
 
 
Total long-lived assets
  
$
466.0     
$
463.0     
$
371.7